Tag Archives: Huntington’s disease

April, 2018

25 April
Ionis’ Investigational Huntington’s Disease Drug Demonstrates Lowering of the Disease-Causing Protein and Improvement in Clinical Measures in Phase 1/2 Study

CARLSBAD, Calif., April 24, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today presented top-line data from the Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington’s disease (HD) at the 70th American Academy of Neurology (AAN) meeting in Los Angeles, California. …
Share

31 August
FDA Approves Teva’s Austedo for Treatment of Tardive Dyskinesia in Adults

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a …
Share

14 July
New Data Network for Huntington’s Disease Research

Huntington’s disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to cell death in neurons in the brain resulting in gradual physical, mental and emotional changes, and ultimately death. Those born to a parent with Huntington’s disease have …
Share

4 April
FDA Approves Teva’s Austedo for Treatment of Chorea Associated with Huntington’s Disease

JERUSALEM–(BUSINESS WIRE)–Apr. 3, 2017– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Previously referred to by the developmental name SD-809, AUSTEDOTM is the first deuterated …
Share

21 October
FDA Accepts Resubmission of Teva’s Huntington Disease Drug

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The FDA has assigned a Prescription Drug User Fee …
Share

11 December
Raptor Announces Plans to Advance Development of Huntington’s Disease Drug

NOVATO, Calif., Dec. 10, 2015 /PRNewswire/ — Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced 36-month efficacy results from a Phase 2/3 clinical trial evaluating RP103 for the potential treatment of Huntington’s disease, called CYST-HD, conducted in collaboration with the Centre Hospitalier Universitaire d’Angers (CHU d’Angers), France. Data from the study revealed …
Share

14 October
Takeda and UCL Enter Research Partnership to Identify Novel Target Genes for Neurodegenerative Disease

LONDON & CAMBRIDGE, England–(BUSINESS WIRE)–UCL (University College London) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease. This collaboration will focus on mechanistic approaches for the identification of genes or signalling pathways that modify …
Share

30 March
Teva Strengthens its CNS Portfolio with its $3.2 Billion Acquisition of Auspex

Today, Teva Pharmaceutical Industries Ltd. announced that it has agreed to acquire central nervous system (CNS) drug developer Auspex Pharmaceuticals, Inc. for about $3.2 billion. The companies said that they have entered into a definitive merger agreement, under which Teva will commence a tender offer for all of the outstanding …
Share